

00827T 00542260

ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or  
SEQ ID NO:10, which molecule (i) immunospecifically  
binds CD40, (ii) increases the binding of CD40  
ligand to CD40 by at least 45%, and (iii) comprises  
one or more substitutions or insertions in primary  
amino acid sequence relative to native monoclonal  
antibody S2C6 as secreted by the hybridoma  
deposited with the ATCC and assigned accession  
number PTA-110, which amount is effective for the  
treatment or prevention of an immune disorder.

31. A method for the treatment or prevention of an  
immune disorder in a subject comprising:

administering to the subject an amount of a  
purified protein, which protein (i) competes for  
binding to CD40 with monoclonal antibody S2C6 as  
secreted by the hybridoma deposited with the ATCC  
and assigned accession number PTA-110, (ii)  
increases the binding of CD40 ligand to CD40 by at  
least 45%, and (iii) comprises one or more  
substitutions or insertions in primary amino acid  
sequence relative to native monoclonal antibody  
S2C6 as secreted by the hybridoma deposited with  
the ATCC and assigned accession number PTA-110,  
which amount is effective for the treatment or  
prevention of an immune disorder.

32. The method of any one of claims 26-31 further  
comprising administering CD40 ligand to the subject.

33. The method of any one of claims 26-31 in which the  
subject is a human.

34. The antibody of claim 3 which is not isotype IgG1.

35. A transgenic non-human animal, plant, or an  
isolated cell containing one or more transgenes encoding a

protein, which protein competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, and which protein increases the binding of CD40 ligand to CD40 by at least 45%.

5

36. A pharmaceutical composition comprising in an amount effective for the treatment or prevention of cancer or an immune disorder, or for activating or augmenting an immune response: (a) a molecule that immunospecifically binds CD40, which molecule increases the binding of CD40 ligand to CD40; (b) CD40 ligand; and (c) a pharmaceutically acceptable carrier.

10

37. A method for the treatment or prevention of cancer or an immune disorder in a subject comprising administering to the subject, in an amount effective for said treatment or prevention: (a) a molecule that immunospecifically binds CD40, which molecule increases the binding of CD40 ligand to CD40; and (b) CD40 ligand.

15

20

25

30

35